Literature DB >> 23063073

The leukotrienes: immune-modulating lipid mediators of disease.

Antonio Di Gennaro1, Jesper Z Haeggström.   

Abstract

The leukotrienes are important lipid mediators with immune modulatory and proinflammatory properties. Classical bioactions of leukotrienes include chemotaxis, endothelial adherence, and activation of leukocytes, chemokine production, as well as contraction of smooth muscles in the microcirculation and respiratory tract. When formed in excess, these compounds play a pathogenic role in several acute and chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. An increasing number of diseases have been linked to inflammation implicating the leukotrienes as potential mediators. For example, recent investigations using genetic, morphological, and biochemical approaches have pointed to the involvement of leukotrienes in cardiovascular diseases including atherosclerosis, myocardial infarction, stroke, and abdominal aortic aneurysm. Moreover, new insights have changed our previous notion of leukotrienes as mediators of inflammatory reactions to molecules that can fine-tune the innate and adaptive immune response. Here, we review the most recent understanding of the leukotriene cascade with emphasis on recently identified roles in immune reactions and pathophysiology.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063073     DOI: 10.1016/B978-0-12-394300-2.00002-8

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  35 in total

1.  Genetic polymorphisms of T-1131C APOA5 and ALOX5AP SG13S114 with the susceptibility of ischaemic stroke in Morocco.

Authors:  Brehima Diakite; Khalil Hamzi; Wiam Hmimech; Sellama Nadifi
Journal:  J Genet       Date:  2016-06       Impact factor: 1.166

2.  Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis.

Authors:  Matthew C Tattersall; Mengye Guo; Claudia E Korcarz; Adam D Gepner; Joel D Kaufman; Kiang J Liu; R Graham Barr; Kathleen M Donohue; Robyn L McClelland; Joseph A Delaney; James H Stein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

Review 3.  Enemy attraction: bacterial agonists for leukocyte chemotaxis receptors.

Authors:  Dominik Alexander Bloes; Dorothee Kretschmer; Andreas Peschel
Journal:  Nat Rev Microbiol       Date:  2014-12-15       Impact factor: 60.633

4.  Evolutionary alteration of ALOX15 specificity optimizes the biosynthesis of antiinflammatory and proresolving lipoxins.

Authors:  Susan Adel; Felix Karst; Àngels González-Lafont; Mária Pekárová; Patricia Saura; Laura Masgrau; José M Lluch; Sabine Stehling; Thomas Horn; Hartmut Kuhn; Dagmar Heydeck
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-13       Impact factor: 11.205

5.  Endogenous Production of Long-Chain Polyunsaturated Fatty Acids and Metabolic Disease Risk.

Authors:  Harvey J Murff; Todd L Edwards
Journal:  Curr Cardiovasc Risk Rep       Date:  2014-12-01

Review 6.  Recent developments in the role of reactive oxygen species in allergic asthma.

Authors:  Jingjing Qu; Yuanyuan Li; Wen Zhong; Peisong Gao; Chengping Hu
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

Review 7.  Eicosanoids and Keratinocytes in Wound Healing.

Authors:  Raja K Sivamani
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-07-01       Impact factor: 4.730

Review 8.  Lipid mediators and allergic diseases.

Authors:  Laura B Fanning; Joshua A Boyce
Journal:  Ann Allergy Asthma Immunol       Date:  2013-07-21       Impact factor: 6.347

9.  Strain-specific red blood cell storage, metabolism, and eicosanoid generation in a mouse model.

Authors:  James C Zimring; Nicole Smith; Sean R Stowell; Jill M Johnsen; Lauren N Bell; Richard O Francis; Eldad A Hod; Jeanne E Hendrickson; John D Roback; Steven L Spitalnik
Journal:  Transfusion       Date:  2013-05-30       Impact factor: 3.157

Review 10.  Leukotriene biosynthetic enzymes as therapeutic targets.

Authors:  Jesper Z Haeggström
Journal:  J Clin Invest       Date:  2018-07-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.